The intervention is a commercial product. The senior author is affiliated with the vendor, and the paper identifies W.H.P. as its Chief Medical Officer. The protocol lists the company as a source of support. Of the two physicians who reviewed summary accuracy, one is that CMO. The authors name this in their limitations and cite mutual blinding and an unaffiliated second reviewer as mitigation.

The mitigation is reasonable for the accuracy check. It does not address trial conduct, outcome framing, or the decision about what to emphasize. Readers should weigh the efficacy findings knowing the developer helped run the study. Independent replication is the usual remedy.

Controls received nothing in writing. The intervention group received a personalized document from the hospital before the visit.

The trial compares "something" with "nothing." Part of the FAPI gain could come from receiving any preparatory material, or from feeling attended to, rather than from AI translation specifically. A comparison against the original document plus a generic leaflet, or a clinician-written summary, would isolate the AI contribution.

The protocol prespecified 0.3 to 0.5 FAPI points as clinically important and powered for it assuming SD 1.0. The observed difference was 0.17 points. Observed SDs were about 0.52, so the standardized effect (g=0.33) looks larger than the raw change. Control scores were already 4.25 of 5. The authors acknowledge all of this in the Discussion.

The result is statistically clear and clinically modest. Read in raw points, it is about one sixth of a point on a five-point scale, near the ceiling. The headline "small-to-moderate" label leans on the standardized metric.

The protocol's only comprehension measure was a single self-rated understanding item. It was not collected "because patients could not quantify their understanding in a single rating." No objective knowledge test was planned.

The stated rationale for the intervention is comprehension. The trial measured how the visit felt, not what the patient understood. A summary that is pleasant but subtly wrong, or that creates false reassurance, would not be detected by any end point here.

Median visit time fell from 33 to 25 minutes. Timing was done by study staff not involved in care but aware of allocation. Data were missing for 15 intervention and 8 control encounters. The Discussion calls this "a meaningful reduction."

This is a secondary, multiplicity-unadjusted end point measured by unblinded staff. Shorter is not automatically better. Physicians in the same arm rated their autonomy support lower and encounter difficulty possibly higher. Whether patients left with fewer unanswered questions, or simply with less time, was not measured. "Efficiency" is an interpretation the data do not yet support.

Dual physician review of 75 summaries found no factual errors, clinically relevant omissions, or harmful statements. All 150 passed a checklist and four LLM judges. The protocol specified dual review of 10%; this was raised to 50% before end point analysis.

By the rule of three, zero events in 75 is compatible with a true error rate up to about 4% (95% upper bound). That is reassuring for a pilot and insufficient for deployment at scale. The paper does not state who performed the checklist review on the remaining 75 summaries. The pipeline also screened outputs before release, so the trial measures a filtered product, not raw model output.

• Model changed from Claude 3.5 (protocol) to Claude 3.7 Sonnet (trial).
• Dual review raised from 10% to 50%.
• Self-rated understanding item dropped.
• Prespecified health literacy subgroup not performed: screening items available for only 174 of 300.
• No standalone SAP before recruitment; the consolidated SAP was assembled during revision, with deviations labeled.

Each change is disclosed, and none touches the primary end point. Together they mean the analysis framework firmed up after the data existed. The lost health literacy subgroup is the most consequential: low-literacy patients are the population the intervention exists for.

The CONSORT diagram shows 300 assessed for eligibility and 0 excluded or declined, despite "consecutive" recruitment over seven months. German proficiency was required. "Previously informed about their condition" is missing for 42% of participants.

A zero-decline flow suggests the screening log was not reported rather than that every approached patient agreed. Without it, the representativeness of the sample is unknown. Excluding non-German speakers removes the group with arguably the most to gain (the authors note this).

Encounters were clustered among 17 physicians. The primary analysis used Welch's t test; a post hoc cluster-robust analysis gave a consistent estimate (0.17; 95% CI 0.02 to 0.32). Secondary end points are unadjusted and explicitly labeled exploratory.

Handled transparently. The cluster-robust interval for the primary end point nearly reaches zero, which is worth knowing. With 17 clusters, cluster-robust estimates are themselves imprecise.

The title says "Effect of." The Conclusions say "associated with," note the physician-side findings, and call for confirmation before routine adoption. The abstract states the primary result was "driven by shared decision-making," which rests on a secondary subscale.

Overall, the abstract and conclusions are more restrained than typical for vendor-adjacent AI trials. The "meaningful reduction" language for consultation time is the main place the Discussion runs ahead of the evidence.